Terms: = Gastric cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H
870 results:
1. [A Case of Advanced gastric cancer Treated with Conversion Surgery followed by Nivolumab Combination Chemotherapy].
Sekino N; Natsume T; Tanaka H; Kainuma O; Sato Y; Note H; Yoshioka T; Kamata T; Odera H; Uchiyama M; Maruyama T; Takahashi H; Hirano S
Gan To Kagaku Ryoho; 2024 Apr; 51(4):417-420. PubMed ID: 38644309
[TBL] [Abstract] [Full Text] [Related]
2. [Enhancing survival outcomes in stage Ⅲ gastric/esophagogastric junction cancer: a retrospective study of immune checkpoint inhibitors and adjuvant chemotherapy based on real-world data].
Yang XQ; Rao Z; Wei HK; Xue ZC; Liu HY; Duan QF; Sun XW; Wang W
Zhonghua Wei Chang Wai Ke Za Zhi; 2024 Apr; 27(4):395-402. PubMed ID: 38644245
[No Abstract] [Full Text] [Related]
3. Identification of TAP1 as a T-cell related therapeutic target in gastric cancer by mediating oxalipliatin-related synergistic enhancement of immunotherapy.
Zhao Y; Liu Z; Deng K; Qu H; Zhang Q; Zhou P; Yang M; Yang X; Wang H; Li R; Xia J
Int Immunopharmacol; 2024 May; 132():111998. PubMed ID: 38593510
[TBL] [Abstract] [Full Text] [Related]
4. HSPA4 upregulation induces immune evasion via ALKBH5/CD58 axis in gastric cancer.
Suo D; Gao X; Chen Q; Zeng T; Zhan J; Li G; Zheng Y; Zhu S; Yun J; Guan XY; Li Y
J Exp Clin Cancer Res; 2024 Apr; 43(1):106. PubMed ID: 38589927
[TBL] [Abstract] [Full Text] [Related]
5. Associations of PD-1 and pd-l1 gene polymorphisms with cancer risk: a meta-analysis based on 50 studies.
Yang M; Liu Y; Zheng S; Geng P; He T; Lu L; Feng Y; Jiang Q
Aging (Albany NY); 2024 Mar; 16(7):6068-6097. PubMed ID: 38546391
[TBL] [Abstract] [Full Text] [Related]
6.
Cytryn SL; Pandit-Taskar N; Lumish MA; Maron SB; Gu P; Ku GY; Chou JF; Capanu M; Antoine A; Loegel D; Feder L; Philemond S; Lyashchenko SK; Lewis JS; Paroder V; Srivastava A; Tang LH; Schoder H; Janjigian YY
J Nucl Med; 2024 May; 65(5):722-727. PubMed ID: 38514081
[TBL] [Abstract] [Full Text] [Related]
7. Serum iron element: A novel biomarker for predicting PD-1 immunotherapy efficacy.
Luan F; Wang J; Liu L; Liu B; Li F; Zhao J; Lai J; Jiang F; Xu W; Zhang Z; Ran P; Shu Y; Yang Z; Fu G
Int Immunopharmacol; 2024 Apr; 131():111823. PubMed ID: 38508094
[TBL] [Abstract] [Full Text] [Related]
8. Body composition change indices combined with Prognostic Nutritional Index predicts the clinical outcomes of patients with gastric cancer treated with immune checkpoint inhibitor.
Deng G; Zhu D; Du Z; Xue Y; Song H; Li Y
Cancer Med; 2024 Mar; 13(6):e7110. PubMed ID: 38506237
[TBL] [Abstract] [Full Text] [Related]
9. Neoadjuvant nivolumab or nivolumab plus LAG-3 inhibitor relatlimab in resectable esophageal/gastroesophageal junction cancer: a phase Ib trial and ctDNA analyses.
Kelly RJ; Landon BV; Zaidi AH; Singh D; Canzoniero JV; Balan A; Hales RK; Voong KR; Battafarano RJ; Jobe BA; Yang SC; Broderick S; Ha J; Marrone KA; Pereira G; Rao N; Borole A; Karaindrou K; Belcaid Z; White JR; Ke S; Amjad AI; Weksler B; Shin EJ; Thompson E; Smith KN; Pardoll DM; Hu C; Feliciano JL; Anagnostou V; Lam VK
Nat Med; 2024 Apr; 30(4):1023-1034. PubMed ID: 38504015
[TBL] [Abstract] [Full Text] [Related]
10. Gastroesophageal Adenocarcinomas With Defective Mismatch Repair: Current Knowledge and Clinical Management.
Strickland MR; Lander EM; Gibson MK; Ilson DH; Ajani JA; Klempner SJ
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38503041
[TBL] [Abstract] [Full Text] [Related]
11. Association of lymphocyte subsets with the efficacy and prognosis of PD‑1 inhibitor therapy in advanced gastric cancer: results from a monocentric retrospective study.
Wang X; Liu X; Dai H; Jia J
BMC Gastroenterol; 2024 Mar; 24(1):113. PubMed ID: 38491354
[TBL] [Abstract] [Full Text] [Related]
12. Specific lineage transition of tumor-associated macrophages elicits immune evasion of ascitic tumor cells in gastric cancer with peritoneal metastasis.
Li Y; Jiang L; Chen Y; Li Y; Yuan J; Lu J; Zhang Z; Liu S; Feng X; Xiong J; Jiang Y; Zhang X; Li J; Shen L
Gastric Cancer; 2024 May; 27(3):519-538. PubMed ID: 38460015
[TBL] [Abstract] [Full Text] [Related]
13. Perioperative or neoadjuvant chemotherapy for locally advanced gastric or gastroesophageal junction cancer: from independent evidence in the West, the East, and Japan to global collaboration.
Nakayama I; Ohashi M; Nunobe S
Chin Clin Oncol; 2024 Feb; 13(1):8. PubMed ID: 38453658
[TBL] [Abstract] [Full Text] [Related]
14. How to use anti-PD-1 therapy in gastric cancer: the approach in the United States.
Ilson DH
Chin Clin Oncol; 2024 Feb; 13(1):7. PubMed ID: 38453657
[TBL] [Abstract] [Full Text] [Related]
15. Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy.
Masetti M; Al-Batran SE; Goetze TO; Thuss-Patience P; Knorrenschild JR; Goekkurt E; Folprecht G; Ettrich TJ; Lindig U; Luley KB; Pink D; Dechow T; Sookthai D; Junge S; Loose M; Pauligk C; Lorenzen S
Int J Cancer; 2024 Jun; 154(12):2142-2150. PubMed ID: 38447003
[TBL] [Abstract] [Full Text] [Related]
16. Prognostic implications of tumor-infiltrating lymphocytes within the tumor microenvironment in gastric cancer.
Pereira MA; Ramos MFKP; Cardili L; de Moraes RDR; Dias AR; Szor DJ; Zilberstein B; Alves VAF; de Mello ES; Ribeiro U
J Gastrointest Surg; 2024 Feb; 28(2):151-157. PubMed ID: 38445936
[TBL] [Abstract] [Full Text] [Related]
17. Correlation of CT parameters and pd-l1 expression status in gastric cancer.
Xu M; Ren T; Deng J; Yang J; Lu T; Xi H; Yuan L; Zhang W; Zhou J
Abdom Radiol (NY); 2024 Apr; 49(4):1320-1329. PubMed ID: 38436699
[TBL] [Abstract] [Full Text] [Related]
18. Case report: A case of rare metastasis of gastric cancer to the axillary lymph node metastasis treated with combination immunotherapy.
Wang J; Cheng Y; Wang Y; Liu H; Wu S; Tian G; Qu J; Qu X
Front Immunol; 2024; 15():1331506. PubMed ID: 38404578
[TBL] [Abstract] [Full Text] [Related]
19. Identification of ferroptosis-related subtypes, characteristics of TME infiltration and development of prognostic models in gastric cancer.
Tang X; Yu Y; Liu N; Su Y; Zhang K; Zhai Z; Chen C; Sun W; Chen D; Ling R
Int Immunopharmacol; 2024 Mar; 130():111610. PubMed ID: 38402832
[TBL] [Abstract] [Full Text] [Related]
20. Real-world outcomes of third-line immune checkpoint inhibitors versus irinotecan-based chemotherapy in patients with advanced gastric cancer: a Korean, multicenter study (KCSG ST22-06).
Lim SH; Lee KW; Kim JJ; Im HS; Kim IH; Han HS; Koo DH; Cho JH; Maeng CH; Lee MY; Lee HJ; Kim JH; Park SG; Jung JY; Shin SH; Kim KH; Kim H; Oh SY; Kang M; Jung M; Rha SY
BMC Cancer; 2024 Feb; 24(1):252. PubMed ID: 38395832
[TBL] [Abstract] [Full Text] [Related]
[Next]
